CytRx Corp. said Wednesday that it has received its 13thpatent on RheothRx. U.S. patent No. 5,041,288 covers the use ofRheothRx for the treatment of reperfusion injury, which occurswhen an organ such as the heart is deprived of blood. CytRx(NASDAQ:CYTR) of Norcross, Ga., has licensed worldwide rightsto RheothRx to Burroughs Wellcome Co. The drug is in Phase Iclinical trials.

(c) 1997 American Health Consultants. All rights reserved.